Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy

1986 ◽  
Vol 22 (3) ◽  
pp. 283-288 ◽  
Author(s):  
Ezzeldin M. Ibrahim ◽  
Hassan Y. Al-Idrissi ◽  
Abdelwahab Ibrahim ◽  
Gamil Absood ◽  
Eman Al-Dossary ◽  
...  
1984 ◽  
Vol 2 (5) ◽  
pp. 466-471 ◽  
Author(s):  
M S Aapro ◽  
P M Plezia ◽  
D S Alberts ◽  
V Graham ◽  
S E Jones ◽  
...  

Nausea and vomiting remain common and debilitating side effects of therapy with many anticancer drugs. Recent reports have shown that both metoclopramide and dexamethasone are effective drugs for the treatment of severe nausea and vomiting caused by cis-platinum. A double-blind crossover study comparing the antiemetic properties of high-dose oral and intravenous regimens of metoclopramide and dexamethasone in outpatients was carried out. Standardized patient questionnaires and interviews were used to evaluate response. Dexamethasone and metoclopramide protected against more than five episodes of emesis in 48% and 40% of patients, respectively. Nausea persisted for less than six hours in 45% of patients on dexamethasone and in 37% on metoclopramide. The antiemetic efficacy of both regimens was retained through repeated courses of chemotherapy. Side effects were minimal with dexamethasone; however, 33% of patients experienced unacceptable extrapyramidal side effects to metoclopramide. Patient preference was significantly in favor of dexamethasone: 70% of patients chose to continue dexamethasone compared to 22% who preferred metoclopramide and 8% who chose other antiemetics. Dexamethasone was the preferred antiemetic in this patient population due to minimal side effects.


2003 ◽  
Vol 23 (6) ◽  
pp. 668-671 ◽  
Author(s):  
Robert R. Conley ◽  
Deanna L. Kelly ◽  
Charles M. Richardson ◽  
Carol A. Tamminga ◽  
William T. Carpenter

Dermatology ◽  
1996 ◽  
Vol 193 (4) ◽  
pp. 324-327 ◽  
Author(s):  
T. Zuberbier ◽  
C. Münzberger ◽  
U. Haustein ◽  
E. Trippas ◽  
B. Burtin ◽  
...  

2006 ◽  
Vol 21 (6) ◽  
pp. 393-398 ◽  
Author(s):  
Deanna L. Kelly ◽  
Charles M. Richardson ◽  
Yang Yu ◽  
Robert R. Conley

1979 ◽  
Vol 42 (02) ◽  
pp. 621-625 ◽  
Author(s):  
G G Nenci ◽  
G Agnelli ◽  
M Berrettini ◽  
P Parise ◽  
E Ballatori

SummaryIn a randomized double-blind crossover study in 16 patients with enhanced in vitro spontaneous platelet aggregation, sulfinpyrazone proved to be effective in normalizing platelet aggregability within 4 days after initiation of therapy.


Sign in / Sign up

Export Citation Format

Share Document